ImmunoGen has announced an agreement granting Vertex Pharmaceuticals rights to conduct research using antibody-drug conjugate (ADC) technology for the discovery of new targeted conditioning agents.
The research using ImmunoGen’s technology will enable the discovery of the agents for use with gene editing.
Upon completion of the research period for each target, Vertex may obtain a global and exclusive license for their research, development and commercialization using the technology for that target.
Vertex is also responsible for the related costs.
Exclusive rights to the technology remain with ImmunoGen for all targets not covered by the Vertex license.
Michael Vasconcelles, Executive Vice President of ImmunoGen Research, Development and Medical Affairs said, “Given Vertex’s extensive experience in discovering and developing transformative medicines for patients with serious diseases, we are thrilled that they have chosen to explore ImmunoGen’s technology to develop ADCs for transplant conditioning in conjunction with gene editing.
“This agreement reflects our continued innovation in the ADC space and demonstrates the value of our technology platform and related intellectual property rights.”
ImmunoGen will receive $15 million. in advance payment from Vertex as part of the international multi-target license and option agreement.
The company will also be eligible for development and commercial milestone payments and option exercise fees of up to $337 million. per Goal.
In addition, Vertex will pay incremental royalties to ImmunoGen as a percentage of global commercial sales of new conditioners.
Senior Vice President of Vertex Cell and Genetic Therapies, Mike Cooke, said: “We look forward to evaluating the potential of ImmunoGen’s technology to develop a milder conditioning regimen for use with Vertex’s exagamglogen autotemcel (exa-cel) for the potential treatment of sickle cell disease (SCD ) and transfusion-dependent beta-thalassemia (TDT).
Early R&D projects’ coverage of pharmaceutical technology is supported by Mimotopes.
Editorial content is independently produced and follows highest standards journalistic integrity. Topic sponsors are not involved in the creation of editorial content.